

Curriculum Vitae Prof. Dr. med. Emanuel Burri



PERSÖNLICHE DATEN

Geburtsdatum 9. Oktober 1975
Geburtsort Basel
Familie verheiratet, 3 Kinder

BERUFLICHER WERDEGANG

01.2022 - dato Chefarzt Klinik Gastroenterologie & Hepatologie, Assoz. Universitäres Zentrum für Innere Medizin, Kantonsspital Baselland

07.2020 - 12.2021 Co-Chefarzt, Medizinische Universitätsklinik, Kantonsspital Baselland

09.2018 - dato Stv. Leiter Darmkrebszentrum, Kantonsspital Baselland

01.2015 - dato Leiter Gastroenterologie, Kantonsspital Baselland

01.2014 - 01.2015 Leitender Arzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland

07.2013 - 12.2013 Oberarzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland

10.2012 - 06.2013 Oberarzt, Gastroenterologie und Hepatologie, Innere Medizin, Stadtpital Triemli, Zürich

07.2011 - 07.2012 Assistenzarzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland

07.2010 - 06.2011 Assistenzarzt, Gastroenterologie und Hepatologie, Universitätsspital Basel

09.2008 - 06.2010 Forschungsassistent, Abteilung für Gastrointestinale Forschung, Universitätsspital Vall d'Hebron, Barcelona, Spanien

04.2008 - 08.2008 Forschungsassistent, Innere Medizin, Universitätsspital Basel

08.2007 - 03.2008 Assistenzarzt, Medizinische Poliklinik, Universitätsspital Basel

10.2004 - 07.2007 Assistenzarzt, Innere Medizin, Universitätsspital Basel

08.2003 - 08.2004 Assistenzarzt, Chirurgische Klinik, Kantonsspital Baselland

03.2002 - 07.2003 Forschungsassistent, Medizinische Universitätsklinik, Kantonsspital Baselland

Kantonsspital Baselland

AKADEMISCHER WERDEGANG

| | |
|------|---|
| 2024 | Titularprofessur Gastroenterologie |
| 2015 | Venia Docendi (Habilitation) Innere Medizin, speziell Gastroenterologie |
| 2014 | Spezialisierung Endoskopische Retrograde Cholangio- Pankreatikographie (ERCP) |
| 2014 | Sachverständigung dosisintensives Röntgen |
| 2012 | Facharzttitle FMH Gastroenterologie |
| 2009 | Facharzttitle FMH Innere Medizin |
| 2007 | Dissertation, Medizinische Fakultät, Universität Basel |
| 2001 | Eidgenössisches Staatsexamen |

INSTITUTIONELLE AKTIVITÄTEN

| | |
|------|--|
| 2023 | Scientific Advisory Board Schweizerische Vereinigung Eosinophile Ösophagitis |
| 2023 | Scientific Advisory Board for Interessensgemeinschaft Zöliakie |
| 2020 | SNEGID Steering Committee Member |
| 2019 | IBDnet Steering Committee Member |
| 2019 | National Representative European Crohn's and Colitis Organization (ECCO) |
| 2018 | IBDnet Operational Committee Member |

MITGLIEDSCHAFTEN

Swiss Association for Internal Medicine (FMH)
Swiss Society of Gastroenterology (SGG)
European Organization for Crohn's and Colitis (ECCO)
Inflammatory Bowel Disease Net (IBDnet)
European Eosinophilic Esophagitis Society (EUREOS)
Swiss Network for Eosinophilic Gastrointestinal Diseases (SNEGID)
European Society of Gastrointestinal Endoscopy (ESGE)
European Society of Neurogastroenterology & Motility (ESNM)
German Society of Neurogastroenterology & Motility (DGNM)

SPRACHEN

Deutsch (Muttersprache), Englisch, Französisch, Spanisch

SCIENTIFIC PUBLICATIONS

Total citations: 6028 (May 2024); H-Index: 41; i10-index: 83

Peer-Reviewed Articles

1. Gueguen E, Morsy Y, Mamie C, Schoepfer A, Saner C, Biedermann L, Straumann A, Kreienbühl A; Swiss **EoE Cohort Study Group**; Scharl M, Wawrzyniak M. *Novel transcriptomic panel identifies histologically active oesinophilic oesophagitis*. Gut. 2024 Apr 26;gutjnl-2023-331743
2. **Burri E**. *Chronisch entzündliche Darmerkrankungen: eine Einführung*. Ther Umsch. 2023 Dec;80(9):377.
3. Sulz MC, Doulberis M, Fournier N, Biedermann L, Zeitz J, Misselwitz B, Imthurn B, Rogler G; SIBDCS Group. *Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study*. J Gastrointest Liver Dis. 2023 Dec 22;32(4):460-468
4. Looser R, Doulberis M, Rossel JB, Franc Y, Müller D, Biedermann L, Rogler G; with support of the **SIBDCS study group***. *Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines*. Ann Gastroenterol. 2023 Nov-Dec;36(6):637-645.
5. Laura Rossier, Christoph Matter¹, **Emanuel Burri**, Tatiana Galperine, Petr Hruz, Pascal Juillerat, Alain Schoepfer, Stephan R. Vavricka, Nadine Zahnd, Natalie Décosterd and Frank Seibold¹ on behalf of IBDnet, an official working group of the Swiss Society of Gastroenterology. *Swiss Expert Opinion: Current Approaches in Fecal Microbiota Transplantation in Daily Practice* Swiss Med Wkly. 2023 Aug 25;153:40100. doi: 10.57187/smw.2023.40100.
6. Scherer R, Schreiner P, Rossel JB, Greuter T, **Burri E**, Saner C, Schlag C, Safroneeva E, Schoepfer A, Straumann A, Biedermann L. *Barrett's Esophagus in Eosinophilic Esophagitis in Swiss Eosinophilic Esophagitis Cohort Study (SEECs)*. Dig Dis. 2023 May 24. doi: 10.1159/000531060. Epub ahead of print. PMID: 37231862.
7. Cathomas M, Rosenberg R, **Burri E**, Javier-Gonzalez M, Weber A, Filipowicz Sinnreich M, Cathomas G, Galli R. *Herpes simplex virus colitis mimicking acute severe ulcerative colitis: a case report and review of the literature*. J Surg Case Rep. 2023 Apr 27;2023(4):rjad225.
8. Abo El Ela A, Meuli N, Hruz P, **Burri E**. *Fecal calprotectin increases the diagnostic yield in patients with suspected small bowel disease - a multicenter retrospective cohort study*. Swiss Medical Weekly 2022 (in press)
9. Lautenschlager SA, Barry MP, Rogler G, Biedermann L, Schreiner P, Siebenhüner AR; **Swiss IBD Cohort Study Group**. *Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study*. BMC Gastroenterol. 2023 Mar 12;23(1):71
10. Vetter M, Bollinger C, Chiru D, Petit-Berli M, Degener K, Seifert B, Rosenberg R, Subotic S, **Burri E**, Leuppi-Taegtmeier A, Zimmermann F, Muri-John V, Javier-Gonzalez M, Zeller A, Unger H. *Integrating Geriatric Care in Clinical Oncology Practice: Recommendations from an Interdisciplinary Professional Survey Study in a Single-Cancer Center in Switzerland*. healthbook TIMES Oncology Hematology. 2023;16(2):14-19. doi:10.36000/hbT.OH.2023.16.106
11. Barba E, **Burri E**, Quiroga S, Accarino A, Azpiroz F. *Visible abdominal distension in functional gut disorders: Objective evaluation*. Neurogastroenterol Motil. 2023 Feb;35(2):e14466
12. Horvath L, Fostiropoulos K, **Burri E**, Kraft M. *Comparison of Transnasal Esophagoscopy and Sedated Esophagogastroduodenoscopy in the Assessment of Laryngopharyngeal Reflux*. Clin Otolaryngol 2022 Dec 19 (Epub ahead of print).
13. Salzmann M, von Graffenried T, Righini-Grunder F, Braegger C, Spalinger J, Schibli S, Schoepfer A, Nydegger A, Pittet V, Sokollik C; **Swiss IBD Cohort Study Group**. *Drug-Related Adverse Events Necessitating Treatment Discontinuation in Pediatric Inflammatory Bowel Disease Patients*. J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):731-736
14. Juillerat P, Angelillo-Scherrer A, Surbek D, Restellini S, Biedermann L, Rogler G, Vavricka, SR, Schoepfer A, **Burri E**, Degen L, Seibold F, Mottet C, Maillard MH, Michetti, P, Battegay E, Stein J. *Modern Intravenous Iron Therapy: A Review on Safety and Practical Aspects*. Ann Hematol Oncol. 2022; 9(6): 1413.
15. Bianchi R, Mamadou-Pathé B, von Känel R, Roth R, Schreiner P, Rossel JB, Burk S, Dora B, Kloth P, Rickenbacher A, Turina M, Greuter T, Misselwitz B, Scharl M, Rogler G, Biedermann L; or the **Swiss IBD cohort study**. *Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients*. PLoS One. 2022 Sep 16;17(9):e0274665.
16. Boesing M, Abig K, Brändle M, Brutsche M, **Burri E**, Frye BC, Giezendanner S, Grutters JC, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeier AB, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi JD. *Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial*. Trials. 2022 Sep 20;23(1):790. doi: 10.1186/s13063-022-06723-w. PMID: 36127739; PMCID: PMC9486780.
17. Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP,

- Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Carrami EM, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM; COLORS in IBD group investigators; Oxford IBD cohort study investigators; INTERVAL Study; **Swiss IBD cohort investigators**; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA. *Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease*. Nat Commun. 2020 Feb 21;11(1):995. doi: 10.1038/s41467-019-14275-y. Erratum in: Nat Commun. 2022 Jun 22;13(1):3576. PMID: 32081864; PMCID: PMC7035382.
18. Jordi SBU, Lang BM, Wyss J, Auschra B, Yilmaz B, Krupka N, Greuter T, Schreiner P, Biedermann L, Preisig M, von Känel R, Rogler G, Begré S, Misselwitz B; **Swiss IBD cohort study group**. *The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients*. J Gastroenterol. 2022 Nov;57(11):848-866.
 19. Lett MJ, Mehta H, Keogh A, Jaeger T, Jacquet M, Powell K, Meier MA, Fofana I, Melhem H, Vosbeck J, Cathomas G, Heigl A, Heim MH, **Burri E**, Mertz KD, Niess JH, Kollmar O, Zech CJ, Ivanek R, Duthaler U, Klenerman P, Stroka D, Filipowicz Sinnreich M. *Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells*. Gut Published Online First: 20 January 2022. doi: 10.1136/gutjnl-2021-324478
 20. Perrig K, Krupka N, Jordi SBU, Rossel JB, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, **Burri E**, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. *Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland*. Therap Adv Gastroenterol. 2022 Feb 9;15:17562848221074188. doi: 10.1177/17562848221074188. eCollection 2022.
 21. Roth R, Vavricka S, Scharl M, Schreiner P, Safroneeva E, Greuter T, Zeitz J, Misselwitz B, Schoepfer A, Barry MP, Rogler G, Biedermann L; **Swiss IBD cohort study**. *The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients*. United European Gastroenterol J. 2021 Sep;9(7):773-780
 22. Pittet LF, Verolet CM, Michetti P, Gaillard E, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM; **Swiss Inflammatory Bowel Disease Cohort Study Group**. *Risk of Vaccine-Preventable Infections in Swiss Adults with Inflammatory Bowel Disease*. Digestion. 2021;102(6):956-964
 23. Yoganathan P, Rossel JB, Jordi SBU, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I; **Swiss IBD cohort study group**. *Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients*. BMC Gastroenterol. 2021 Aug 3;21(1):310. doi: 10.1186/s12876-021-01880-9. PMID: 34344313; PMCID: PMC8336111.
 24. **Burri E**, Ansprenger C. [Interventional endoscopy in hepatico-pancreatico-biliary disease]. Ther Umsch. 2021;78(10):575-584. doi: 10.1024/0040-5930/a001313
 25. Yoganathan P, Rossel JB, Jordi SBU, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I; **Swiss IBD cohort study group**. *Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients*. BMC Gastroenterol. 2021 Aug 3;21(1):310. doi: 10.1186/s12876-021-01880-9
 26. Horvath L, Fostiropoulos K, **Burri E**, Kraft M. *Value of Transnasal Esophagoscopy in the Workup of Laryngopharyngeal Reflux*. J. Clin. Med. 2021, 10, 3188
 27. Jordi SBU, Lang BM, Auschra B, von Känel R, Biedermann L, Greuter T, Schreiner P, Rogler G, Krupka N, Sulz MC, Misselwitz B, Begré S; **Swiss IBD Cohort Study Group**. *Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease*. Inflamm Bowel Dis. 2022 Mar 30;28(4):560-571.
 28. Horvath L, Hagmann P, **Burri E***, Kraft M*. *Evaluation of Oropharyngeal pH-Monitoring in the Assessment of Laryngopharyngeal Reflux*. J. Clin. Med. 2021, 10, 2409. Online ahead of print.
 29. Schoepfer AM, Henchoz S, Biedermann L, Schreiner P, Greuter T, Reinhard A, Senn J, Franke A, **Burri E**, Juillerat P, Simon HU, Straumann A, Safroneeva E, Godat S. *Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis*. Gastrointest Endosc. 2021 May 15:S0016-5107(21)01352-3. doi: 10.1016/j.gie.2021.05.017. Online ahead of print.
 30. Jordi SBU, Botte F, Lang BM, Greuter T, Krupka N, Auschra B, Schreiner P, Sulz MC, Biedermann L, von Känel R, Rogler G, Begré S, Misselwitz B; **Swiss IBD cohort study group**. *Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease*. Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365. Online ahead of print. PMID: 33975385
 31. Horvath L, Hagmann P, **Burri E***, Kraft M*. *A Novel Scoring System for Evaluating Laryngopharyngeal Reflux*. Clin Otolaryngol. 2021 Jan 27. doi: 10.1111/coa.13721. Online ahead of print
 32. Ledergerber M, Lang BM, Heinrich H, Biedermann L, Begré S, Zeitz J, Krupka N, Rickenbacher A, Turina M, Greuter T, Schreiner P, Roth R, Siebenhüner A, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; **Swiss IBD Cohort Study Group**. *Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management*. BMC Gastroenterol. 2021 Feb 5;21(1):53. doi: 10.1186/s12876-021-01622-x.
 33. Ruiz F, Wyss A, Rossel JB, Sulz MC, Brand S, Moncsek A, Mertens JC, Roth R, Clottu AS, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B; **Swiss IBD Cohort Study Group**. *A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with*

Kantonsspital Baselland

- inflammatory bowel disease*. Br J Pharmacol. 2021 Aug;178(16):3157-3175. doi: 10.1111/bph.15395. Epub 2021 Mar 10. PMID: 33511653.
34. Yoganathan P, Rossel JB, Jordi SBU, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I; **Swiss IBD cohort study group**. *Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients*. BMC Gastroenterol. 2021 Aug 3;21(1):310. doi: 10.1186/s12876-021-01880-9. PMID: 34344313; PMCID: PMC8336111.
 35. Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH; **Swiss IBD Cohort Study group**. *Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data*. J Crohns Colitis. 2020 May 21;14(4):490-500. doi: 10.1093/ecco-jcc/jjz169. PMID: 31630164.
 36. Schreiner P, Rossel JB, Biedermann L, Valko PO, Baumann CR, Greuter T, Scharl M, Vavricka SR, Pittet V, Juillerat P, Rogler G, von Känel R, Misselwitz B; **Swiss IBD Cohort Study Group**. *Fatigue in inflammatory bowel disease and its impact on daily activities*. Aliment Pharmacol Ther. 2021 Jan;53(1):138-149. doi: 10.1111/apt.16145. Epub 2020 Nov 7.
 37. Sulz MC, **Burri E**, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F. *Treatment Algorithms for Crohn's Disease*. Digestion 2020 Mar 13:1-15
 38. Wuggenig P, Kaya B, Melhem H, Ayata CK; **Swiss IBD Cohort Investigators**, Hruz P, Sayan AE, Tsumura H, Ito M, Roux J, Niess JH. *Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice*. Commun Biol. 2020 Mar 18;3(1):130
 39. Serra EG, Schwerdt T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP, Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Karaminejadranjbar M, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM; **COLORS in IBD group investigators**; Oxford IBD cohort study investigators; **INTERVAL Study**; **Swiss IBD cohort investigators**; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA. *Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease*. Nat Commun. 2020 Feb 21;11(1):995. doi: 10.1038/s41467-019-14275-y.
 40. **Burri E**, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S. *Position statement on the use of biosimilars in inflammatory bowel disease*. Swiss Med Wkly. 2019 Dec 2;149:w20148. doi: 10.4414/smw.2019.20148. eCollection 2019 Dec 2.
 41. **Burri E**, Maillard MH, Schoepfer AM, Seibold F, Van Asche G, Riviere P, Laharie D, Manz M. *Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update*. Digestion 2020 Jan 16:1-14
 42. Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; **Swiss IBD Cohort Study Group**. *Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study*. Dig Dis Sci. 2019 Dec 3
 43. Barba E, Sánchez B, **Burri E**, Accarino A, Monclus E, Navazo I, Guarner F, Margolles A, Azpiroz F. *Abdominal distension after eating lettuce: The role of intestinal gas evaluated in vitro and by abdominal CT imaging*. Neurogastroenterol Motil. 2019 Aug 11 (epub ahead of print)
 44. Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, Pittet VEH; **Swiss IBD Cohort Study Group**. *The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years*. J Crohns Colitis. 2019 May 27;13(6):744-754. doi: 10.1093/ecco-jcc/jjz003. PMID: 30916775.
 45. Pittet V, Michetti P, Mueller C, Braegger CP, von Känel R, Schoepfer A, Macpherson AJ, Rogler G; **Swiss IBD Cohort Study Group**. *Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)*. Int J Epidemiol. 2019 Apr 1;48(2):385-386f. doi: 10.1093/ije/dyy298. PMID: 30689927.
 46. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; **Swiss IBD Cohort Investigators**, Wiest R, Stelling J, Macpherson AJ. *Microbial network disturbances in relapsing refractory Crohn's disease*. Nat Med. 2019 Jan 21.
 47. Tcybarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, Scharl M, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; **Swiss IBD Cohort Study Group**. *The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation*. BMC Gastroenterol. 2019 Jan 7;19(1):2
 48. Greuter T, Piller A, Fournier N, Safroneeva E, Straumann A, Biedermann L, Godat S, Nydegger A, Scharl M, Rogler G, Vavricka SR, Schoepfer AM; **Swiss IBD Cohort Study Group**. *Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course*. J Crohns Colitis. 2018 Nov 28;12(12):1399-1409. doi: 10.1093/ecco-jcc/jjy121. PMID: 30165603.
 49. Pittet VEH, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P; **Swiss IBD Cohort Study Group(*)**. *Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals*. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2050-2059.e1. doi: 10.1016/j.cgh.2018.11.029. Epub 2018 Nov 22. PMID: 30471455.

Kantonsspital Baselland

50. Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, **Burri E**, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M. *The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding*. United European Gastroenterol J. 2018 Aug;6(7):1007-1014.
51. Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; **Swiss IBD Cohort Study Group**. *Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study*. J Crohns Colitis. 2018 Jun 28;12(7):811-818
52. Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, Nydegger A, Spalinger J, Schibli S, Petit LM, Braegger CP; **Swiss IBD Cohort Study Group**. *Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications*. Eur J Gastroenterol Hepatol. 2018 Jun;30(6):598-607. doi: 10.1097/MEG.0000000000001072. PMID: 29360691.
53. Ansprenger C, **Burri E**. *Diagnose und Monitoring bei chronisch-entzündlichen Darmerkrankungen*. Therapeutische Umschau (2018), 75(5), 316-328
54. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; **Swiss IBD Cohort Study Group**. *Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort*. Eur J Gastroenterol Hepatol. 2018 Jun;30(6):612-620. doi: 10.1097/MEG.0000000000001078. PMID: 29384798.
55. Girardin M, Hadengue A, Frossard JL; **Swiss IBD Cohort Study Group**. *High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients*. World J Clin Cases. 2018 Apr 16;6(4):44-53. doi: 10.12998/wjcc.v6.i4.44. PMID: 29670889; PMCID: PMC5902505.
56. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M; **Swiss IBD Cohort Study Group**. *The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort*. Inflamm Bowel Dis. 2018 Apr 13. [Epub ahead of print].
57. Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Bègré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; **Swiss IBD Cohort Study Group**. *Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease*. Aliment Pharmacol Ther. 2018 Jan;47(1):55-66. Epub 2017 Oct 20.
58. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; **Swiss IBD Cohort Study Group**. *Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator*. PLoS One. 2017 Feb 10;12(2):e0171864. doi: 10.1371/journal.pone.0171864. PMID: 28187201; PMCID: PMC5302448.
59. Bendezú RA, Barba E, **Burri E**, Cisternas D, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Colonic content in health and its relation to functional gut symptoms*. Neurogastroenterol Motil. 2016 Jun;28(6):849-54. (IF 2.94, Rank 29/74).
60. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; **Swiss IBD Cohort Study Group**. *Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease*. Clin Gastroenterol Hepatol. 2016 Jun;14(6):829-835.e1. (IF 6.65, Rank 8/74).
61. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; **Swiss IBD Cohort Study**. *Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?* J Crohns Colitis. 2016 Mar;10(3):269-76. (IF 3.56, Rank 20/74)
62. Bendezú RA, Barba E, **Burri E**, Cisternas D, Malagelada C, Segui S, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Intestinal gas content and distribution in health and in patients with functional gut symptoms*. Neurogastroenterol Motil. 2015 Jun 21 [Epub ahead of print] (IF 2.94, Rank 29/74).
63. **Burri E**, Beglinger C, Lehmann FS. Reply: To PMID 25344905. Dig Dis Sci. 2015 Apr;60(4):1109-10.
64. Lehmann FS, **Burri E**, Beglinger C. *The role and utility of faecal markers in IBD*. Therap Adv Gastroenterol. 2015 Jan;8(1):23-36. Review.
65. Barba E*, **Burri E***, Accarino A, Cisternas D, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Abdominothoracic mechanisms of functional abdominal distension and correction by biofeedback*. *Equal contributors. Gastroenterology. 2015 Apr;148(4):732-9 (IF 13.93, Rank 1/74).
66. **Burri E**, Beglinger C, von Felten S, Lehmann FS. *Faecal calprotectin and the Clinical Activity Index are both useful to monitor medical treatment in patients with ulcerative colitis*. Dig Dis Sci. 2015 Feb;60(2):485-91. Epub 2014 Oct 26. (IF 2.55, Rank 28/74)
67. Vavricka SR, Radivojevic S, Manser CN, Frei P, **Burri E**, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. *Addressing current treatment challenges in Crohn's disease in real life: a physician's survey*. Dig Liver Dis. 2014 Dec;46(12):1066-71. Epub 2014 Aug 29. (IF 2.89, Rank 28/74)
68. Barba E, **Burri E**, Accarino A, Malagelada C, Rodriguez-Urrutia A, Soldevilla A, Malagelada JR, Azpiroz F. *Biofeedback-guided control of abdominothoracic muscular activity reduces regurgitation episodes in patients with rumination*. Clin Gastroenterol Hepatol. Clin Gastroenterol Hepatol. 2015 Jan;13(1):100-6.e1. Epub 2014 Apr 24. (IF 6.65, Rank 8/74).
69. **Burri E**, Beglinger C. *Faecal calprotectin testing - the need for better standardization*. Nat Rev Gastroenterol Hepatol 2014 Oct;11(10):583-4. (IF 10.42, Rank 4/74)

Kantonsspital Baselland

70. **Burri E**, Manz M, Schroeder P, Froehlich F, Rossi L, Beglinger C, Lehmann FS. *Diagnostic yield of endoscopy in patients with abdominal complaints: Incremental value of fecal calprotectin on guidelines of appropriateness*. BMC Gastroenterol. 2014 Mar 29;14(1):57. Epub 2013 May 23. (IF 2.11, Rank 42/74)
71. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; **Swiss IBD Cohort Study Group**. *Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis*. J Crohns Colitis. 2014 Aug 1;8(8):825-34 (IF 3.56, Rank 20/74)
72. **Burri E**, Beglinger C. *The use of fecal calprotectin as a biomarker in gastrointestinal disease*. Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):197-210. Epub 2013 Dec 18 (IF 2.22, Rank 38/74).
73. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; **Swiss IBD Cohort Study Group**. *Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease*. Digestion. 2013;87(3):212-21. Epub 2013 May 23. (IF 1.94, Rank 46/74).
74. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevila A, Eng E, Malagelada JR, Azpiroz F. *Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia*. Gut. 2014 Mar;63(3):395-400. Epub 2013 May 4. (IF 10.73, Rank 3/74).
75. Barba E, Quiroga S, Accarino A, Monclus Lahoya I, Malagelada C, **Burri E**, Malagelada JR, Azpiroz F. *Mechanisms of abdominal distension in severe intestinal dysmotility: abdomino-thoracic response to gut retention*. Neurogastroenterol Motil. 2013 Jun;25(6):e389-94. Epub 2013 Apr 22. (IF 2.94, Rank 29/74).
76. **Burri E**, Schulte F, Muser J, Meier R, Beglinger C. *Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count*. World J Gastroenterol. 2013 Apr 7;19(13):2028-36. (IF 2.55, Rank 34/74).
77. **Burri E**, Vavricka SR. *Perianal Crohn's Disease*. Ther Umsch. 2013 Jul;70(7):417-28.
78. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevila A, Eng E, Malagelada JR, Azpiroz F. *Abdominal accommodation induced by meal ingestion: differential responses to gastric and colonic volume loads*. Neurogastroenterol Motil. 2013 Apr;25(4):339-e253. Epub 2013 Jan 29. (IF 2.94, Rank 29/74).
79. **Burri E**, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. *Monoclonal antibody testing for faecal calprotectin is superior to polyclonal testing of faecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort*. Clin Chim Acta. 2013 Feb 1;416:41-7. Epub 2012 Nov 21. (IF 2.85, Rank 6/32).
80. **Burri E**, Hochholzer K, Arenja N, Martin-Braschler H, Kaestner L, Gekeler H, Hatzisaska T, Büttiker M, Fräulin A, Potocki M, Breidhardt T, Reichlin T, Socrates T, Twerenbold R, Mueller C. *B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care*. J Intern Med. 2012 Nov;272(5):504-13. Epub 2012 Jun 12. (IF 6.46, Rank 10/155).
81. **Burri E**, Beglinger C, Lehmann FS. *Monitoring of therapy for inflammatory bowel disease*. Digestion 2012;86 Suppl 1:1-5. Epub 2012 Oct 5 (IF 1.94, Rank 46/74).
82. **Burri E**, Beglinger C. *Fecal calprotectin - A useful tool in the management of inflammatory bowel disease*. Swiss Medical Weekly. Swiss Med Wkly. 2012 Apr 5;142 (IF 1.82, Rank 50/155).
83. Klima T, Christ A, Marana I, Kalbermatter S, Uthoff H, **Burri E**, Hartwiger S, Schindler C, Breidhardt T, Marenzi G, Mueller C. *Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial*. Eur Heart J. 2012 Aug;33(16):2071-9. Epub 2012 Jan 19. (IF 14.10, Rank 2/124).S
84. **Burri E**, Toia D, Meier R. *Triple pylorus*. Endoscopy 2012;44 Suppl 2 UCTN:E362. Epub 2012 Sept 25. (IF 5.74, Rank 9/74).
85. Manz M*, **Burri E***, Rothen C, Tchanguzi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. *Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study*. BMC Gastroenterol. 2012 Jan 10;12(1):5. *Equal contributors (IF 2.11, Rank 29/74).
86. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevilla A, Malagelada JR, Azpiroz F. *Accommodation of the abdomen to its content: integrated abdomino-thoracic response*. Neurogastroenterol Motil. 2012 Apr;24(4):312-e162. Epub 2011 Dec 21. (IF 2.94, Rank 29/74).
87. **Burri E**, Manz M, Rieder S, Beglinger C. *Limited value of fecal calprotectin in patients with liver cirrhosis*. Scand J Gastroenterol. 2011 Dec;46(12):1527-8. (IF 2.16, Rank 40/74).
88. **Burri E**, Potocki M, Drexler B, Schuetz P, Mebazaa A, Ahlfeld U, Balmelli C, Heinisch C, Noveanu M, Breidhardt T, Schaub N, Reichlin T, Mueller C. *Value of arterial blood gas analysis in patients with acute dyspnea: an observational study*. Crit Care. 2011 Jun 9;15(3):R145. (IF 4.72, Rank 5/27).
89. Villoria A, Azpiroz F, **Burri E**, Cisternas D, Soldevilla A, Malagelada, JR. *Abdomino-phrenic dyssynergia in patients with abdominal bloating and distension*. Am J Gastroenterol. 2011 May;106(5):815-9. (IF 7.75, Rank 7/74).
90. **Burri E**, Beglinger, C. *Diagnostic value of faecal calprotectin in inflammatory bowel disease*. Biochem Med. 2011;21(3):245-53 (IF 1.87, Rank 13/32).
91. Reichlin T, Potocki M, Breidhardt T, Noveanu M, Hartwiger S, **Burri E**, Klima T, Stelzig C, Laule K, Mebazaa A, Christ M, Mueller C. *Diagnostic and prognostic value of uric acid in patients with acute dyspnea*. Am J Med. 2009 Nov;122(11):1054.e7-1054.e14. (IF 5.12, Rank 14/153).
92. Manz M, **Burri E**, Degen L, Beglinger C, Vavricka SR. *Serum protein electrophoresis: An underused but very useful test*. Digestion. 2009;79(4):203-10. Epub 2009 Apr 9. Review. (IF 1.94, Rank 46/74).
93. Vavricka SR, Manz M, **Burri E**. *Trichuris trichiura (Whipworm)*. Clin Gastroenterol Hepatol. 2009 Oct;7(10):A16. Epub 2008 Dec 13. (IF 5.29, Rank 38/72).
94. **Burri E**, Meier R. *Malnutrition in hospitals - A pilot study*. Praxis (Bern 1994). 2008 Jun 11;97(18):657-63. German.

Kantonsspital Baselland

95. Khanlari B, **Burri E**, Mihatsch F, Flückiger U, Battegay M. *Mycobacterium avium pneumonia in an HIV negative patient*. Internist (Berl). 2007 May;48(5):527-31. German
96. **Burri E**, Duwe J, Kull C, Glaser C, Maurer CA. *Pulmonary vein thrombosis after lower lobectomy of the left lung*. J Cardiovasc Surg (Torino). 2006 Oct;47(5):609-12.
97. **Burri E**, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R. *Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver*. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):437-41. Review.
98. Meier R, **Burri E**, Steuerwald M. *The role of nutrition in diarrhoea syndromes*. Curr Opin Clin Nutr Metab Care. 2003 Sep;6(5):563-7. Review.

Other Publications

1. Raichle, C. **Burri E**. *Erkrankungen der Gallenwege und des Pankreas - Diagnostisches Vorgehen und endoskopische Verfahren*. Leading Opinions Innere Medizin 2023
2. Mariann Szabo, **Burri E**. *Magen und Darm: Sensible Hochleistungsorgane*. Hausarzt Praxis 2019;14(1):2
3. Hitz L, **Burri E**. *Helicobacter pylori. Heute noch ein Problem in der hausärztlichen Praxis?* Der informierte @rzt. 2018;01:16-17.
4. **Burri E**, Beglinger C, Biedermann L, Michetti P, Nydegger A, Schoepfer A, Seibold F, Vavricka S, Rogler G. *Diagnostischer Nutzen von Calprotectin im klinischen Alltag*. Schweiz Med Forum 2016;16(03):68-73
5. **Burri E**. *Blähungen bei funktionellen Darmerkrankungen*. Leading Opinions Innere Medizin 2015;02:40-44.
6. Kraft M, Frischknecht J, Michel J, Fostiropoulos K, **Burri E**, Brosi P, Köberle R, Rosenberg R, Tschopp K. *Oropharyngelae 24h-pH-Metrie bei laryngopharyngealem Reflux*. Schweiz Med Forum 2015;15(29-30):684-687.
7. **Burri E**. *Calprotectin im klinischen Alltag*. Leading Opinions Innere Medizin 2014:46-49.
8. **Burri E**, Meier R. *Ulkuskrankheit - Update 2011*. Swiss Med Forum 2011;11(49):897-906
9. **Burri E**, Nuesch R, Lugli A, Vavricka S. *Early gastric cancer--or not*. Praxis (Bern 1994). 2008 Dec 17;97(25):1351-5. German
10. Brendebach S, **Burri E**, Imfeld S, Jacob AL, Zimmerli L. *Non-controllable blood pressure peaks--pheochromocytoma?* Praxis (Bern 1994). 2008 Dec 17;97(25):1357-61. Germ
11. **Burri E**, Zulewski H, Nuesch R. *Hyperprolactinemia in a man's world*. Praxis (Bern 1994). 2008 Dec 3;97(24):1295-9. German
12. **Burri E**, Decker M, Eriksson U, Buser P, Hunziker L. *28-year old patient with successfully treated dilatative cardiomyopathy*. Internist (Berl). 2008 Mar;49(3):349-52. German.
13. **Burri E**, Rüegg S, Rutishauser J, Egger SS, Lampert ML. *Subtherapeutic blood levels of phenytoin due to a medication error*. Praxis (Bern 1994). 2007 Apr 25;96(17):687-92. German.
14. **Burri E**, Laffer R, Steuerwald M, Cathomas G, Zimmerli W. *Fever, malaise and new onset mitral valve insufficiency. Subacute Streptococcus bovis mitral valve endocarditis*. Praxis (Bern 1994). 2004 May 5;93(19):819-22. German.
15. **Burri E**, Steuerwald M, Maurer CA, Toia D, Cathomas G, Meier R. *Cystic space-occupying lesion of the liver as an incidental finding. Symptomatic Echinococcus granulosus cyst of the right hepatic lobe*. Praxis (Bern 1994). 2003 May 28;92(22):1051-4. German

Book Chapters

1. Christoph A. Maurer and **Emanuel Burri**. *Proximal Rectal Adenocarcinoma*, in Clinical Scenarios in Surgical Oncology, ed. Vijay P. Kathri, 136-139, Philadelphia: Lippincott Williams & Wilkins 2006
2. Christoph A. Maurer and **Emanuel Burri**. *Distal Rectal Adenocarcinoma*, in Clinical Scenarios in Surgical Oncology, ed. Vijay P. Kathri, 140-145, Philadelphia: Lippincott Williams & Wilkins 2006

Oral Presentations/Posters

1. Elena D Chiru, Marie Knufike, Martina Sonderegger-Stalder, Raphael Mosimann, Antonia Sgries, Robert Rosenberg, **Emanuel Burri**, Sandra Mitrovic, Michèle Voegeli, Kristen Mertz, Alessandra Angelini, Marcus Vetter. *Prognostic value of serum biomarkers in pancreatic adenocarcinoma: Results from a Swiss single center cohort analysis*. Cancer Research 2024;84(6):6_Supplement
2. B Ricken, L Brosi, C Reinhard, L Anchling, S Neu, J Afonso, T Schuster, E Wütherich, **E Burri**, S Paul, AE Berger, W Guirao, M Barrau, L Bastide, X Roblin, V Pflimlin-Fritschy, U Rutscher, P Hruz, CB Gerhold. *Feasibility study of a Point-of-Care assay for rapid determination of anti-TNFa biologics in capillary blood*. Journal of Crohn's and Colitis 2024;18;Supplement_1
3. MHF Vetter, C Ewald, **E Burri**, R Rosenberg, S Subotic, S Mitrovic, ED Chiru, M Knufinke. *Biomarker of blood age and inflammation in older cancer patients might predict outcome*. Annals of Oncology 2023;34:S269
4. Catherine Saner, Eaterina Safroneeva, Jean-Benoit Rossel, **Emanuel Burri**, Patrick Aepli, Annett Franke, Luc Biedermann, Thomas Greuter, Peter Netzer, Alex Straumann, Alain Schoepfer; *SECS group Update 2023 on the Swiss Eosinophilic Esophagitis Cohort* (Swiss Congress of Gastroenterology, Interlaken). Swiss Medical Weekly 2023;153 (Suppl. 272)
5. P Häuptle, K Mertz, M Voegeli, R Robert, **E Burri**, S Subotic, A Romanens, A Leuppi-Taegtmeier, R Christian, L Wedeken, M Vetter. *Tailored Anti-Cancer treatment in elderly cancer patients A registry study in Progress*. Journal of Geriatric Oncology 2022;13(8):S7-S8

Kantonsspital Baselland

6. Christoph Matter, Audrey Fahrny, Marc Fellmann, Jan Hendrik Niess, **Emanuel Burri**, Luc Biedermann, Stephan Robert Vavricka, Tim Killeen. *A Swiss Study to Investigate Real-world Clinical, Biochemical and Patient-reported Responses to Tofacitinib Induction Therapy for Ulcerative Colitis: Rationale and Study Design*. Swiss Medical Weekly;152:19S-19S
7. K Roosen, L Schupp, D Mitas, P Molteni, S Lamm, **E Burri**, R Rosenberg, R Galli. *How can we reduce the use of antibiotics in acute uncomplicated diverticulitis-a multifactorial intervention*. Swiss Medical Weekly;152:15S-15S
8. Galli R, Mitas D, Molteni P, **Burri E**, Lamm S, Rosenberg R. *A multifactorial intervention to reduce use of antibiotics in acute uncomplicated diverticulitis-a single centre feasibility study*. British Journal of Surgery 2022 109 (Supplement_3), znc181. 010
9. Fellay B, Drzewicka M, **Burri E**, Ueberschlag ME, Ritz A, Wieland J, Schneider M. *Quantum Blue® fCAL extended POC user performance evaluation*. Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, 16 January 2018, Page S498-S499. Poster presentation UEGW 2017.
10. Fellay B, Kopertowska-Majchrzak M, **Burri E**, Ueberschlag ME, Ritz A, Schuster T. *Quantum Blue® infliximab POC user performance evaluation*. Journal of Crohn's and Colitis 12(supplement_1):S499. Poster presentation UEGW 2017.
11. Vavricka S, Heinrich H, Misselwitz B, Buetschkofer S, **Burri E**, Rogler G, Breitenmoser F, Schneider X, Zeitz J, Biedermann L, Sauter M. *Ingestion of 100ml and 300ml blood mimicking upper gi bleeding leads to significant calprotectin elevation in healthy volunteers - results from the "Vampire study"*. Journal of Crohn's and Colitis, Volume 11, Issue suppl_1, 1 February 2017, Pages S142-S143. Poster presentation UEGW 2016.
12. **Burri E**, Meuli N, Beglinger C. *Diagnostic value of fecal calprotectin to detect small bowel pathology in patients with previous negative endoscopy*. Oral presentation UEGW 2014.
13. **Burri E**, Meuli N, Beglinger C. *Diagnostic value of fecal calprotectin to detect small bowel pathology in patients with previous negative endoscopy*. Oral presentation SGG 2014.
14. Barba E, **Burri E**, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Origin of abdominal distension: is it in the chest after all?* Oral presentation UEGW 2013.
15. **Burri E**, Barba E, Hernandez C, Cisternas D, Accarino A, Malagelada JR. *Abdominal bloating is associated to abdomino-phrenic dyssynergia*. Oral presentation UEGW 2012.
16. **Burri E**, Niederberger C, Beglinger C. *Calprotectin measurement in ascitic fluid: a new test for the rapid diagnosis of spontaneous bacterial peritonitis*. Oral presentation SGG 2011.
17. **Burri E**, Accarino A, Azpiroz F. *Bloating and distension in functional gastrointestinal disorders results from abdomino-phrenic muscle dyssynergia*. Poster presentation SGG 2011.
18. **Burri E**, Huaman W, Hernandez C, Accarino A, Malagelada JR, Azpiroz F. *Abdomino-phrenic dyssynergia in patients with functional dyspepsia*. Oral presentation UEGW 2011.
19. **Burri E**, Niederberger C, Beglinger C. *Calprotectin measurement in ascitic fluid: a new test for the rapid diagnosis of spontaneous bacterial peritonitis*. Oral presentation UEGW 2011.
20. **Burri E**, Azpiroz F, Cisternas D, Accarino A, Malagelada JR. *Abdominal accommodation: specific response to upper gut filling*. Oral presentation UEGW 2010.
21. **Burri E**, Azpiroz F, Hernandez C, Hernandez C, Accarino A, Malagelada JR. *Biofeedback treatment of abdominal distension: a proof-of-concept*. Poster presentation UEGW 2010.
22. **Burri E**, Potocki M, Schütz P, Eriksson U, Taegtmeier A, Niederhauser N, Noveanu M, Breithardt T, Schaub N, Reichlin T, Müller C. *Diagnostic and prognostic value of arterial blood gas analysis in patients with acute dyspnea*. Poster presentation SGIM 2009.
23. Manz M, **Burri E**, Niederberger C, Rothen C, Beglinger C. *Faecal calprotectin predicts upper gastrointestinal pathology*. Poster presentation UEGW 2009.
24. **Burri E**, Meier R. *Nutritional assessment and nutritional intervention in medical in-patients*. Poster presentation ESPEN 2006.
25. Duwe J, **Burri E**, Toia D, Nussbaumer P, Maurer CA. *Embolization of a high-output aortocaval fistula: an endovascular transfemoral bidirectional approach*. Poster presentation SGC 2004.
26. **Burri E**, Duwe J, Abitabile P, Cathomas G, Maurer CA. *Fibrolamellar Carcinoma in a Male Caucasian*. Oral presentation SGC 2004.
27. **Burri E**, Duwe J, Kocher M, Kull C, Maurer CA. *Pulmonary Vein Thrombosis after Lobectomy*. Oral presentation SGC 2004.
28. **Burri E**, Antoniou E, Drewe J, Meier R. *The effect of different proton pump inhibitors on gastric acidity in volunteers on the first and third day of treatment*. Poster presentation UEGW 2003.
29. **Burri E**, Glaser C, Cathomas G, Maurer CA. *Adenoma of the ampulla vateri: a cause for secondary biliary cirrhosis*. Oral presentation SGC 2003.



April 2024